皮肤弥漫大B细胞淋巴瘤通过IL-10诱导巨噬细胞免疫抑制表型
该研究利用本机构建立的PCDLBCL-LT细胞系ARSI,揭示肿瘤细胞通过分泌IL-10等因子不依赖细胞接触地诱导巨噬细胞发生表型、转录和功能改变,IL-10/IL-10RA阻断可抑制该极化,且巨噬细胞反过来促进肿瘤增殖和耐多柔比星。
要点
- PCDLBCL-LT细胞通过分泌IL-10等因子不依赖接触诱导巨噬细胞M2样极化
- IL-10/IL-10RA阻断可抑制肿瘤细胞诱导的巨噬细胞极化
- 巨噬细胞促进PCDLBCL-LT细胞增殖并增强其对多柔比星的耐药
核心结论
- PCDLBCL-LT细胞通过IL-10分泌塑造免疫抑制性巨噬细胞微环境,且巨噬细胞反馈促进肿瘤增殖和耐药。
研究设计与样本
- 利用本机构建立的PCDLBCL-LT细胞系ARSI,与来源于原代单核细胞和THP-1细胞系的巨噬细胞共培养。
- 使用不同患者来源异种移植的PCDLBCL-LT细胞及4种其他DLBCL细胞系进行验证。
主要发现
- ARSI细胞诱导巨噬细胞发生表型、转录和功能改变,且不需要细胞-细胞接触。
- ARSI分泌组蛋白质组分析显示IL-10等多种影响巨噬细胞的细胞因子和趋化因子高浓度存在。
- IL-10/IL-10RA相互作用阻断可抑制肿瘤细胞诱导的巨噬细胞极化。
- 在4种其他DLBCL细胞系中,仅MYD88突变的OCI-Ly3细胞系表现出类似效应。
- 巨噬细胞增强肿瘤细胞增殖并促进对多柔比星的耐药。
临床怎么用
- 提示IL-10/IL-10RA轴可能是PCDLBCL-LT微环境靶向治疗的潜在干预靶点。
- 巨噬细胞介导的耐药提示联合微环境调控可能改善化疗反应。
局限性
- 主要基于ARSI细胞系及体外共培养模型,需进一步体内验证。
- 其他DLBCL细胞系中仅MYD88突变者表现类似效应,机制普适性待明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type (PCDLBCL-LT) is a rare subset of DLBCL that exhibits genetic features shared with LBCL of immune-privileged sites (notably the MYD88L265P mutation) and is enriched in tumor-associated macrophages expressing M2 markers. Using a unique PCDLBCL-LT cell line (ARSI cell line) developed in our institute, we sought to mechanistically decipher the interplay between lymphoma cells and macrophages. We demonstrate that ARSI cells induce phenotypic, transcriptional, and functional changes in macrophages obtained from primary monocytes and THP-1 cell line. These changes do not require cell-cell contact, and proteome analysis of ARSI secretome reveals high concentration of several cytokines and chemokines known to affect macrophages, including interleukin-10 (IL-10). We then demonstrate that IL-10/Interleukin 10 receptor subunit alpha (IL-10RA) interaction blockade inhibits macrophage polarization induced by tumor cells. These findings are reproduced when macrophages are cocultured with PCDLBCL-LT cells from different patient-derived xenografts. However, among 4 other DLBCL cell lines, only the MYD88-mutated OCI-Ly3 cell line exhibits similar effects, which highlights the variability of macrophage interplays and led us to hypothesize that macrophage shaping, beyond the cutaneous localization, may rely on specific genetics of tumor cells. Finally, we reveal that macrophages enhance tumor cell proliferation and promote resistance to doxorubicin in coculture. In conclusion, these results confirm the robustness of this model to study lymphoma cell and macrophage interplays, underline the critical role of IL-10 in lymphoma microenvironment modeling, and may contribute to better defining its specificities in an era of rising microenvironment-targeted therapies.
引用
- Galtier J, Peanne R, Le Morvan V, et al. Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion. Blood Adv. 2026. PMID: 41358745. doi:10.1182/bloodadvances.2025016492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。